** Shares of medical device maker Tandem Diabetes Care TNDM.O rise 3.5% to $33.8

** Company says U.S. FDA has granted clearance for its automated insulin delivery device, Control-IQ+, for patients with type 2 diabetes

** The device is already approved by the FDA among patients with type 1 diabetes

** TNDM expects the device to be available for new and existing customers in the U.S. by March of this year

** Stock has risen 13.1% in the past 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))